Neural Compensation, Visual Function and Visual Quality After Monofocal or Multifocal Intraocular Lens Implantation

Summary

Multifocal intraocular lenses (MIOLs) provide enhanced far and near visual acuity, but they can bring about halos and glare, which are caused by design deficiencies of the IOLs. Compared to monofocal intraocular lens, pseudo accommodation in nonphysiological state may increase the difficulty of neural compensation reconstruction in patients with multifocal intraocular lens implantation. Patients enrolled into the study will be followed for 1 year and will have study visits preoperatively, at 1 week, 3 months, 6 months, 12 months postoperatively.In this trial, we aimed to specify the time of neural compensation reconstruction in patients and to explore the changes of visual function in senile patients with monofocal or multifocal intraocular lens implantation.

Conditions

• Cataract

Interventions

PROCEDURE

multifocal intraocular lens implantation

In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.

PROCEDURE

monofocal intraocular lens implantation

In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group

DRUG

Dexamethasone

All patients received subconjunctival dexamethasone (2 mg) during surgery

DEVICE

multifocal intraocular lens (IOL) (Tecnis ZMB00)

DEVICE

monofocal intraocular lens (IOL) (Tecnis ZCB)

Sponsors & Collaborators

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Weirong Chen, M.D. · Zhongshan Ophthalmic Center, Sun Yat-sen University

• Yizhi Liu, M.D.;Ph.D. · Zhongshan Ophthalmic Center, Sun Yat-sen University

• Haotian Lin, M.D.;Ph.D. · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-01-31

Primary Completion

2019-01-31

Completion

2019-01-31

Countries

• China

Study Locations